References

1Engerman R, Bloodworth JM Jr, Nelson S: Relationship of microvascular disease in diabetes to metabolic control.

Diabetes 1977;26:760–769.

2Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, Klein R, Klein BE, Zimmet P, Shaw J: Relation between fasting glucose and retinopathy for diagnosis of diabetes: three pop- ulation-based cross-sectional studies.

Lancet 2008;371:736–743.

3Early Treatment Diabetic Retinopathy Study Research Group: Early photoco-

agulation for diabetic retinopathy. ETDRS report No. 9. Ophthalmology 1991;98:766–785.

4Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–820.

5La Selva M, Beltramo E, Pagnozzi F, Bena E, Molinatti PA, Molinatti GM, Porta M: Thiamine corrects delayed replication and decreases production of

lactate and advanced glycation endproducts in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 1996;39: 1263–1268.

6Hammes HP, Du X, Edelstein D Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I,

Brownlee M: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294–299.

7Berrone E, Beltramo E, Solimine C, Ape AU, Porta M: Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular

cells cultured in high glucose. J Biol Chem 2006;281:9307–9313.

8Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ: Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine.

Diabetes 2003;52:2110–2120.

9Donnelly R, Idris I, Forrester JV: Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol 2004;88:145–151.

10Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Depen- dent Diabetes Mellitus. Lancet 1998;35:28–31.

11Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B, ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829–840.

12Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, Lu J, McG Thom SA, Grobbee DE, Stolk RP, on behalf of the AdRem* project team and ADVANCE management committee: Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009; Epub ahead of print; DOI 10.1007/s00125–009–1457-x.

13Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK, DIRECT Programme Study Group: Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394–1402.

14Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N, DIRECT Programme Study Group: Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008;372:1385–1393.

15Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40–51.

16Porta M, Bandello F: Diabetic retinopathy. A clinical update. Diabetologia 2002;45:1617–1634.

17The DAMAD Study Group: Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicentre randomized controlled clinical trial. Diabetes 1989;38:491– 498.

18The TIMAD Study Group: Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990;108:1577–1583.

19Early Treatment of Diabetic Retinopathy Study Group: Effects of aspirin treatment of diabetic retinopathy. ETDRS Report No. 8. Ophthalmology 1991;98:757–765.

20Haritoglou C, Gerss J, Sauerland C, Kampik A, Ulbig MW for the CALDIRET study group: Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebocontrolled, multicentre trial. Lancet 2009;373:1364–1371.

21Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d’Emden MC, Crimet DC, O’Connell RL, Colman PG, FIELD study investigators: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687– 1697.

22O’Doherty M, Dooley I, Hickey-Dwyer M: Interventions for diabetic macular oedema: a systematic review of the literature. Br J Ophthalmol 2008;92:1581– 1590.

23Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving H-H: Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003;26:1258–1264.

24Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK: The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII. The twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008;115:1859–1868.

25The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group: Mod- ern-day clinical course of type 1 diabetes mellitus after 30 years’ duration. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983– 2005). Arch Intern Med 2009;169:1307– 1316.

26Zhang LY, Krzentowski G, Albert A, Lefevbre PJ: Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001;24:1275–1279.

27Grant RW, Buse JB, Meigs JB, for the University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team: Quality of Diabetes Care in U.S. Academic Medical Centers. Low rates of medical regimen change. Diabetes Care 2005;28:337–442.

28Prèvost G, Phan TM, Mounier-Venier C, Fontaine P: Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes Metab 2005;31:479–485.

29De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield F, Kaplan SH, Rossi MCE, Sacco M, Tognoni G, Valentini M, Nicolucci A: Quality of care and outcomes in type 2 diabetic patients. A comparison between general practice and diabetes clinics. Diabetes Care 2005;28:2637– 2643.

30Gill GV, Woodward S, Pradhan S, Wallymahmed M, Groves T, English P, Wilding JP: Intensified treatment of type 2 diabetes. Positive effects on blood pressure but not glycaemic control. Q J Med 2003;96:833–836.

31Saunders SA, Wallymahmed M, Macfarlane IA: Glycaemic control in a type 1 diabetes clinic for younger adults. Q Med J 2004;97:575–580.

32Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, Bellaire S, Raben A, on behalf of the Insulin Aspart Pregnancy Study Group: Maternal glycemic control and hypoglycemia in Type 1 diabetic pregnancy. A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007;30:771–776.

33Ford ES, Little RR, Li C, Mokdad AH: Trends in A1c concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008;31:102–104.

34The DCCT/EDIC Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381–389.

35Caballero S, Sengupta N, Afzal A, Chang KH, Li Calzi S, Guberski DL, Kern TS, Grant MB: Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes 2007;56:960–967.

36Uhlmann K, Kovacs P, Boettcher Y, Hammes HP, Paschke R: Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes 2006;114:275–294.

37The Diabetes Control and Complications Trial Research Group: Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 1997;46:1829–1839.

38Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suñer D, Cigudosa JC, Urioste M, Benitez J, Boix-Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P, Vaag A, Stephan Z, Spector TD, Wu YZ, Plass C, Esteller M: Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005;102:10604–10609.

39El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M: Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008;205:2409–2417; erratum in J Exp Med 2008;205:2683.